TNFSF11 and breast carcinoma: Other pre-clinical combination therapies can also be tested on this xenograft model, where large-scale clinical studies can investigate the effectiveness of therapies such as combined TRAIL receptor agonists alongside RANKL inhibitors to assess the optimal therapeutic regimens in the treatment of breast cancer.